Errik B. Anderson

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.

Wheeler Bio, Inc. is a biomanufacturing company based in the biomanufacturing metro of Oklahoma City, OK. Wheeler Bio's technology platform, Portable CMC™, simplifies the path between drug discovery and clinical manufacturing, providing a new bridge for translating discoveries to first-in-human trials. The company's hub-and-spoke operational model, integrated with biotechs and discovery CROs, revolutionizes the speed of drug development. Wheeler Bio offers a different CDMO model to help innovators go faster with candidates, accelerating processes for plasmids, cell lines, characterization, and more. The company's biologics CDMO facility offers protein expression, cell line development, process development, analytical development, and material supply and testing capabilities. The company was founded by a team of industry experts and strategic investors, led by Jesse McCool who has been the CEO since incorporation.

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.

Vernal Biosciences, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that specializes in manufacturing and formulating mRNA and LNP-mRNA. Vernal's focus is on democratizing access to their expertise and unparalleled LNP-platform technologies to accelerate the potential of mRNA. The American company provides comprehensive high purity platform manufacturing solutions for mRNA-based medicines, from research to clinical development. Vernal Biosciences is pioneering the custom development and manufacturing process for a variety of applications including vaccine development, gene replacement, and more. The company was founded in 2021 and is headquartered just outside of an undisclosed location. The company was founded by Cobaugh Christian, who has been the CEO since incorporation.

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.

Vernal Biosciences, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that specializes in manufacturing and formulating mRNA and LNP-mRNA. Vernal's focus is on democratizing access to their expertise and unparalleled LNP-platform technologies to accelerate the potential of mRNA. The American company provides comprehensive high purity platform manufacturing solutions for mRNA-based medicines, from research to clinical development. Vernal Biosciences is pioneering the custom development and manufacturing process for a variety of applications including vaccine development, gene replacement, and more. The company was founded in 2021 and is headquartered just outside of an undisclosed location. The company was founded by Cobaugh Christian, who has been the CEO since incorporation.

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.

Mytide Therapeutics, Inc. is a peptide and biopolymer manufacturing and computational biology company based in Massachusetts. Mytide's focus is on eliminating the time-consuming and labor-intensive chemical and screening processes that prevent innovative therapeutics from reaching the clinic. The American company's quick-turn manufacturing technology, combined with AI-enabled predictive analytics, provides access to a novel peptide space for the discovery and therapeutic manufacturing of difficult-to-make natural and non-natural peptide and peptide conjugates. The company was founded by Dale Thomas and has been led by CEO Martina Diekmann since 2023.

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.

Vernal Biosciences, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that specializes in manufacturing and formulating mRNA and LNP-mRNA. Vernal's focus is on democratizing access to their expertise and unparalleled LNP-platform technologies to accelerate the potential of mRNA. The American company provides comprehensive high purity platform manufacturing solutions for mRNA-based medicines, from research to clinical development. Vernal Biosciences is pioneering the custom development and manufacturing process for a variety of applications including vaccine development, gene replacement, and more. The company was founded in 2021 and is headquartered just outside of an undisclosed location. The company was founded by Cobaugh Christian, who has been the CEO since incorporation.

Wheeler Bio, Inc. is a biomanufacturing company based in the biomanufacturing metro of Oklahoma City, OK. Wheeler Bio's technology platform, Portable CMC™, simplifies the path between drug discovery and clinical manufacturing, providing a new bridge for translating discoveries to first-in-human trials. The company's hub-and-spoke operational model, integrated with biotechs and discovery CROs, revolutionizes the speed of drug development. Wheeler Bio offers a different CDMO model to help innovators go faster with candidates, accelerating processes for plasmids, cell lines, characterization, and more. The company's biologics CDMO facility offers protein expression, cell line development, process development, analytical development, and material supply and testing capabilities. The company was founded by a team of industry experts and strategic investors, led by Jesse McCool who has been the CEO since incorporation.

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.